Cancer Plasticity: The Role of mRNA Translation.

Antineoplastic Agents / pharmacology Cell Plasticity / drug effects Disease Progression Drug Resistance, Neoplasm / drug effects Epithelial-Mesenchymal Transition / drug effects Eukaryotic Initiation Factor-2 / genetics Eukaryotic Initiation Factor-4F / genetics Gene Expression Regulation, Neoplastic / drug effects Genetic Heterogeneity Humans Mutation Neoplasms / drug therapy Oxidative Phosphorylation / drug effects Protein Biosynthesis / drug effects Tumor Microenvironment / drug effects Warburg Effect, Oncologic / drug effects
cancer plasticity mRNA translation metabolism protein synthesis stromal–epithelial interactions therapy resistance tumor microenvironment

Journal

Trends in cancer
ISSN: 2405-8025
Titre abrégé: Trends Cancer
Pays: United States
ID NLM: 101665956

Informations de publication

Date de publication:
02 2021
Historique:
received: 17 07 2020
revised: 08 09 2020
accepted: 15 09 2020
pubmed: 18 10 2020
medline: 1 10 2021
entrez: 17 10 2020
Statut: ppublish

Résumé

Tumor progression is associated with dedifferentiated histopathologies concomitant with cancer cell survival within a changing, and often hostile, tumor microenvironment. These processes are enabled by cellular plasticity, whereby intracellular cues and extracellular signals are integrated to enable rapid shifts in cancer cell phenotypes. Cancer cell plasticity, at least in part, fuels tumor heterogeneity and facilitates metastasis and drug resistance. Protein synthesis is frequently dysregulated in cancer, and emerging data suggest that translational reprograming collaborates with epigenetic and metabolic programs to effectuate phenotypic plasticity of neoplasia. Herein, we discuss the potential role of mRNA translation in cancer cell plasticity, highlight emerging histopathological correlates, and deliberate on how this is related to efforts to improve understanding of the complex tumor ecology.

Identifiants

DOI: 10.1016/j.trecan.2020.09.005 PMID: 33067172 PMC: PMC8023421
pubmed: 33067172
pii: S2405-8033(20)30261-2
doi: 10.1016/j.trecan.2020.09.005
pmc: PMC8023421
mid: NIHMS1633023
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Eukaryotic Initiation Factor-2 0
Eukaryotic Initiation Factor-4F 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

134-145

Subventions

Organisme : NCI NIH HHS
ID : R01 CA202021
Pays : United States

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Références

Mol Cell. 2000 Nov;6(5):1099-108
pubmed: 11106749
J Natl Cancer Inst. 2016 Sep 15;109(1):
pubmed: 27634934
J Gen Physiol. 1927 Mar 7;8(6):519-30
pubmed: 19872213
Science. 1994 Aug 5;265(5173):803-6
pubmed: 8047887
Biochem Soc Trans. 2015 Jun;43(3):328-32
pubmed: 26009171
Cell. 2005 May 6;121(3):411-23
pubmed: 15882623
Oncogene. 2017 Nov 23;36(47):6640-6648
pubmed: 28783176
Genome Res. 2016 May;26(5):636-48
pubmed: 26984228
Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):179-84
pubmed: 21173232
EMBO J. 2010 Jun 16;29(12):2082-96
pubmed: 20473272
Cell Metab. 2015 Mar 3;21(3):479-92
pubmed: 25738462
Nucleic Acids Res. 2019 Jul 26;47(13):7035-7048
pubmed: 31114929
Genes Dev. 2004 Dec 1;18(23):2893-904
pubmed: 15545625
Mol Cell Biol. 2002 Oct;22(19):6681-8
pubmed: 12215525
Genes Dev. 2006 Mar 1;20(5):557-70
pubmed: 16510872
J Biol Chem. 2013 Jun 28;288(26):18732-42
pubmed: 23667251
J Biol Chem. 2008 Jun 13;283(24):16309-19
pubmed: 18430730
EMBO J. 1997 Apr 15;16(8):1909-20
pubmed: 9155017
PLoS One. 2015 Mar 27;10(3):e0118033
pubmed: 25816351
Cell Metab. 2018 Nov 6;28(5):706-720.e6
pubmed: 30122555
Cancer Res. 2015 Feb 15;75(4):687-97
pubmed: 25524901
Sci Transl Med. 2019 Jul 31;11(503):
pubmed: 31366581
Eur Urol Focus. 2019 May;5(3):433-442
pubmed: 29229583
RNA. 2007 Jul;13(7):1116-31
pubmed: 17488873
Annu Rev Biochem. 2019 Jun 20;88:307-335
pubmed: 31220979
Nature. 2019 Feb;566(7744):403-406
pubmed: 30728499
Cell. 2013 May 23;153(5):1064-79
pubmed: 23706743
Proc Natl Acad Sci U S A. 2018 Mar 06;115(10):E2202-E2209
pubmed: 29463754
Sci Signal. 2015 Nov 17;8(403):ra116
pubmed: 26577921
Mod Pathol. 2016 Dec;29(12):1586-1593
pubmed: 27562491
Cancer Cell. 2013 Mar 18;23(3):316-31
pubmed: 23453623
Nat Commun. 2020 May 19;11(1):2498
pubmed: 32427827
Cancer Cell. 2017 Mar 13;31(3):411-423
pubmed: 28292439
Nucleic Acids Res. 2012 Oct;40(19):9738-49
pubmed: 22904067
Biochim Biophys Acta Gen Subj. 2019 Mar;1863(3):644-649
pubmed: 30572003
Oncotarget. 2018 Sep 4;9(69):33064-33076
pubmed: 30237852
Gynecol Oncol. 2012 Nov;127(2):390-7
pubmed: 22864111
Sci Signal. 2015 Mar 10;8(367):ra27
pubmed: 25759478
Nucleic Acids Res. 2013 Sep;41(17):7997-8010
pubmed: 23851566
Nat Metab. 2019 Sep;1(9):861-867
pubmed: 31598584
Cancer Res. 2011 Jun 1;71(11):4015-27
pubmed: 21512133
Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3120-5
pubmed: 10077647
Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19345-50
pubmed: 18032601
Science. 2020 Apr 24;368(6489):
pubmed: 32327570
Stem Cells Transl Med. 2012 Nov;1(11):811-24
pubmed: 23197693
Oncogene. 2014 Sep 18;33(38):4697-708
pubmed: 24681955
Wiley Interdiscip Rev RNA. 2018 Nov;9(6):e1491
pubmed: 29989343
Cell Stem Cell. 2020 Aug 6;27(2):270-283.e7
pubmed: 32516567
Oncogene. 2018 Feb 1;37(5):651-662
pubmed: 28991229
Cell. 2011 Nov 11;147(4):789-802
pubmed: 22056041
Cold Spring Harb Perspect Biol. 2018 Jul 2;10(7):
pubmed: 29440070
BMC Cancer. 2019 Jun 24;19(1):618
pubmed: 31234823
Dev Cell. 2019 May 6;49(3):361-374
pubmed: 31063755
Mol Cell Biol. 2012 Sep;32(17):3585-93
pubmed: 22751931
Pharmacol Res. 2018 Nov;137:193-204
pubmed: 30316903
Curr Stem Cell Res Ther. 2012 May;7(3):197-216
pubmed: 22329582
FASEB J. 2012 Jun;26(6):2620-30
pubmed: 22415309
Mol Cell. 2006 Feb 17;21(4):521-31
pubmed: 16483933
Mol Cell. 2017 Dec 7;68(5):885-900.e6
pubmed: 29220654
Cancer Res. 2017 May 1;77(9):2213-2221
pubmed: 28249905
Mol Biol Cell. 2002 May;13(5):1792-801
pubmed: 12006670
Nat Rev Mol Cell Biol. 2020 Apr;21(4):183-203
pubmed: 31937935
Clin Cancer Res. 2014 Sep 15;20(18):4733-6
pubmed: 24944315
Mol Cell Biol. 2002 Nov;22(21):7405-16
pubmed: 12370288
RNA. 2014 May;20(5):594-608
pubmed: 24647661
Mol Cell Biol. 1998 Jun;18(6):3112-9
pubmed: 9584152
Nat Commun. 2018 Aug 3;9(1):3068
pubmed: 30076308
PLoS One. 2015 Sep 25;10(9):e0139076
pubmed: 26406898
J Clin Oncol. 2018 Jan 10;36(2):210-216
pubmed: 29220296
Cell Metab. 2018 Dec 4;28(6):817-832.e8
pubmed: 30244971
Cancer Res. 2019 Apr 1;79(7):1646-1657
pubmed: 30659022
Science. 2008 Jun 13;320(5882):1496-501
pubmed: 18497260
Genes Dev. 2019 Oct 1;33(19-20):1355-1360
pubmed: 31439631
J Cancer Metastasis Treat. 2019;5:
pubmed: 31681852
Nat Commun. 2019 May 6;10(1):2065
pubmed: 31061416
Trends Cancer. 2017 Apr;3(4):249-252
pubmed: 28718436
Genome Biol. 2015 May 06;16:90
pubmed: 25943107
Nat Rev Drug Discov. 2015 Apr;14(4):261-78
pubmed: 25743081
Cancer Cell. 2009 May 5;15(5):402-15
pubmed: 19411069
Eur J Cancer. 2017 Oct;84:193-201
pubmed: 28822889
Cancer Discov. 2014 Jun;4(6):702-15
pubmed: 24705811
Oncogene. 2015 Apr 16;34(16):2032-42
pubmed: 24909168
Cell Metab. 2019 Feb 5;29(2):254-267
pubmed: 30581118
Nat Commun. 2019 May 8;10(1):2110
pubmed: 31068593
Cell Stem Cell. 2008 May 8;2(5):448-60
pubmed: 18462695
Mol Cell Biol. 2006 Dec;26(24):9517-32
pubmed: 17030613
PLoS One. 2012;7(5):e36775
pubmed: 22615809
Nature. 2017 Aug 3;548(7665):112-116
pubmed: 28723898
Genes Dev. 2017 Jan 1;31(1):18-33
pubmed: 28096186
EMBO J. 2020 Jan 2;39(1):e102190
pubmed: 31755573
Cancer Cell Int. 2019 Aug 31;19:224
pubmed: 31496918
J Biol Chem. 1997 Dec 19;272(51):32061-6
pubmed: 9405401
Trends Cancer. 2020 Jan;6(1):49-61
pubmed: 31952781
Science. 2016 Jun 17;352(6292):1413-6
pubmed: 27313038
Mol Cell Biol. 2006 May;26(10):3955-65
pubmed: 16648488
Cell Rep. 2016 Feb 16;14(6):1293-1300
pubmed: 26854219
Cancer Lett. 2013 Nov 28;341(1):46-55
pubmed: 23228634
Cell Metab. 2013 Nov 5;18(5):698-711
pubmed: 24206664
Clin Cancer Res. 2018 Apr 15;24(8):1965-1973
pubmed: 29180607
Genes Dev. 2012 Sep 1;26(17):1926-44
pubmed: 22899010
Nat Med. 2016 Mar;22(3):298-305
pubmed: 26855148
Stem Cells. 2009 Jun;27(6):1265-75
pubmed: 19489092
EMBO J. 1997 Apr 15;16(8):1921-33
pubmed: 9155018
Am J Clin Pathol. 2009 Mar;131(3):376-82
pubmed: 19228643
Cell Stem Cell. 2014 May 1;14(5):606-16
pubmed: 24630793
Dev Cell. 2016 Mar 7;36(5):540-9
pubmed: 26954548
J Clin Invest. 2017 Nov 1;127(11):4179-4192
pubmed: 29035277
Cell. 2017 Apr 6;169(2):361-371
pubmed: 28388417
Cell Metab. 2020 Mar 3;31(3):472-492
pubmed: 32130880
Mol Cell Biol. 2015 May;35(10):1788-804
pubmed: 25755286
Cancers (Basel). 2020 Apr 08;12(4):
pubmed: 32276464
Mol Cell Biol. 2018 May 29;38(12):
pubmed: 29610153
Mol Cell. 2001 Jun;7(6):1165-76
pubmed: 11430820
Nature. 2012 May 06;486(7401):126-9
pubmed: 22678294
Biochem Biophys Res Commun. 2010 Apr 9;394(3):600-5
pubmed: 20214883
Cell Rep. 2018 Oct 30;25(5):1109-1117.e5
pubmed: 30380403
Proc Natl Acad Sci U S A. 2016 Apr 5;113(14):E2047-56
pubmed: 27001847
Nature. 1994 Oct 27;371(6500):762-7
pubmed: 7935836
Nat Commun. 2015 Mar 11;6:6377
pubmed: 25758528
Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12238-12243
pubmed: 27791010
Cancer Cell. 2019 Jul 8;36(1):17-34.e7
pubmed: 31287989
Sci Transl Med. 2018 May 2;10(439):
pubmed: 29720449
Proc Natl Acad Sci U S A. 2016 Nov 1;113(44):12360-12367
pubmed: 27791185
Prog Lipid Res. 2013 Oct;52(4):585-9
pubmed: 24001676
Cell Cycle. 2015;14(4):473-80
pubmed: 25590164
PLoS One. 2012;7(11):e48237
pubmed: 23144858
Cancer Res. 2009 Oct 1;69(19):7507-11
pubmed: 19752085
Cell Metab. 2017 Jan 10;25(1):27-42
pubmed: 27641100
Nature. 2016 Aug 4;536(7614):96-9
pubmed: 27462815
Oncogene. 2019 Feb;38(7):1093-1105
pubmed: 30209362
Cell. 2015 Jul 30;162(3):552-63
pubmed: 26232225
Lancet Oncol. 2015 Apr;16(4):e165-72
pubmed: 25846096
Cancer Res. 2010 Dec 15;70(24):10433-44
pubmed: 21159654
Science. 1997 Jul 4;277(5322):99-101
pubmed: 9204908
Cell Stem Cell. 2010 Jul 2;7(1):78-89
pubmed: 20621052
Cancer Cell. 2017 Oct 9;32(4):474-489.e6
pubmed: 29017058
Nat Commun. 2016 Apr 04;7:11127
pubmed: 27040916
Nat Med. 2019 Feb;25(2):301-311
pubmed: 30643286
Cell. 2017 Oct 5;171(2):358-371.e9
pubmed: 28985563
Trends Biochem Sci. 2018 Nov;43(11):882-895
pubmed: 29789219
Cancer Res. 2015 Feb 1;75(3):544-53
pubmed: 25644265
Cancer Prev Res (Phila). 2012 Mar;5(3):355-64
pubmed: 22086681
Genes Dev. 2016 Aug 1;30(15):1698-703
pubmed: 27492367

Auteurs

Laura J Lee (LJ)

Department of Oncology, University of Alberta, Edmonton, AB, Canada.

David Papadopoli (D)

Lady Davis Institute, Gerald Bronfman Department of Oncology and Departments of Biochemistry and Experimental Medicine, McGill University, Montreal, QC, Canada.

Michael Jewer (M)

Department of Oncology, University of Alberta, Edmonton, AB, Canada.

Sonia Del Rincon (S)

Lady Davis Institute, Gerald Bronfman Department of Oncology and Departments of Biochemistry and Experimental Medicine, McGill University, Montreal, QC, Canada.

Ivan Topisirovic (I)

Lady Davis Institute, Gerald Bronfman Department of Oncology and Departments of Biochemistry and Experimental Medicine, McGill University, Montreal, QC, Canada. Electronic address: ivan.topisirovic@mcgill.ca.

Mitchell G Lawrence (MG)

Biomedicine Discovery Institute Cancer Program, Prostate Cancer Research Group, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC 3800, Australia; Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia. Electronic address: mitchell.lawrence@monash.edu.

Lynne-Marie Postovit (LM)

Department of Oncology, University of Alberta, Edmonton, AB, Canada; Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada. Electronic address: l.postovit@queensu.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Cancer Plasticity: The Role of mRNA Translation.
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transdifférenciation cellulaire › Plasticité cellulaire › Cancer Plasticity: The Role of mRNA Translation.
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Évolution de la maladie › Cancer Plasticity: The Role of mRNA Translation.
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance aux médicaments antinéoplasiques › Cancer Plasticity: The Role of mRNA Translation.
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transdifférenciation cellulaire › Transition épithélio-mésenchymateuse › Cancer Plasticity: The Role of mRNA Translation.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines ribosomiques › Facteurs initiation chaîne peptidique › Facteurs d'initiation eucaryotes › Facteur-2 d'initiation eucaryote › Cancer Plasticity: The Role of mRNA Translation.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines ribosomiques › Facteurs initiation chaîne peptidique › Facteurs d'initiation eucaryotes › Facteur-4F d'initiation eucaryote › Cancer Plasticity: The Role of mRNA Translation.
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Régulation de l'expression des gènes tumoraux › Cancer Plasticity: The Role of mRNA Translation.
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Hétérogénéité génétique › Cancer Plasticity: The Role of mRNA Translation.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Cancer Plasticity: The Role of mRNA Translation.
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Cancer Plasticity: The Role of mRNA Translation.
questionsmedicales.fr › Tumeurs › Cancer Plasticity: The Role of mRNA Translation.
questionsmedicales.fr › Métabolisme › Phosphorylation › Phosphorylation oxydative › Cancer Plasticity: The Role of mRNA Translation.
questionsmedicales.fr › Phénomènes génétiques › Expression des gènes › Biosynthèse des protéines › Cancer Plasticity: The Role of mRNA Translation.
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Microenvironnement cellulaire › Microenvironnement tumoral › Cancer Plasticity: The Role of mRNA Translation.
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Respiration cellulaire › Effet Warburg en oncologie › Cancer Plasticity: The Role of mRNA Translation.